The contract research organisation (CRO), which previously ran its US operations from Boston, has units in sought after research markets like South America, Central Europe and the Middle East and North Africa (MENA), including one it opened in Egypt last October.
Pavone, who used to manage operations at Pfizer’s internal contract research unit, told Outsourcing-pharma that marketing this global presence to North American drugmakers was a key motivation for the firm’s latest move.
“US Pharma knows that developing a strong presence in the Emerging Markets is essential. Outsourcing to experts in this area makes for good clinical practice and certainly good business sense.”
“I think partnering with an experienced, established entity [in emerging markets] just makes good business sense.”
She went on to say that: “The addition of the new office and personnel is about enhancing client relations - communications with existing clients as well as clear, informative message to rest of the US Market as to what ClinTec has to offer.”
Pavone also explained that, while direct collaboration with the pharmaceutical industry will be the focus of Clintec’s US operations, the firm is willing to entertain partnering with CROs that lack international reach in response to client requests.
And in wider market terms, Pavone is confident that the contract research market is recovering after the slowdown that has accompanied the global economic downturn over the last few years.
“ClinTec has experienced its greatest increase in signed contracts, permanent staff and global outreach since its inception in 1997. As the state of business continues to improve, I believe the demand of expert CRO services will increase in record numbers.”